trial

A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia

NCTId NCT07191483
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Recruiting
Enrollment 150 (estimated)
Sponsored by Kynexis B.V.
Primary completion 2026-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Recruiting
Enrollment
150 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2025-08-27
Primary completion
2026-10
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
KYN-5356 low doseKYN-5356 Medium DoseKYN-5356 High Dose

Sponsors

Kynexis B.V.Lead Sponsor

Sites

15 total
Little Rock, United StatesCerritos, United StatesLemon Grove, United StatesLos Alamitos, United StatesBoynton Beach, United StatesHollywood, United StatesMiami Lakes, United StatesAtlanta, United StatesDecatur, United StatesChicago, United StatesGaithersburg, United StatesSt Louis, United States

Linked catalysts

1
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With — primary completion2026-10

Facts & assertions

4 sourced
Enrollment
150
Phase
PHASE2
Primary Completion Date
2026-10
Status
RECRUITING
relationships
The graph out of here
drug
KYN-5356 low dose
drug
KYN-5356 Medium Dose
drug
KYN-5356 High Dose
drug
lead_sponsor
Kynexis B.V.
company
indication
Cognitive Impairment Associated With Schizophrenia (CIAS)
indication
Schizophrenia
indication
Cognitive Dysfunction
indication